BioTrinity Testimonials 2009


All testimonials are reproduced with kind permission from their authors, and were comments received in the days and weeks following the conference.

"I found it a very useful event and look forward to attending again next year."
Dr Kaasim Mahmood, Advent Venture Partners 


 “Both the investor dinner and BioTrinity were very good.  Great atmosphere that was very conducive to networking at the dinner.  And the meeting itself was well organized, with a well-structured venue that enabled easy oscillation between plenary sessions and one-on-ones with companies.”

Graham E Fagg, Partner, Seroba Kernel Life Sciences (Ireland’s largest VC)


"BioTrinity has grown every year: from 0 to 140mph in only a few short years. I see it as the central forum for the Biosciences to meet and talk about interesting progressions within the industry"
Matthew Walls, CEO, Epistem


 "I will be happy to participate in this great event again."
Maciek Drozdz, Associate, Entrepreneurs Fund

 


 

"BioTrinity is an excellent opportunity for our continental EU based fund to meet UK based innovative companies and VC colleagues."
Olivier Litzka, Edmond de Rothschild Investment Partners


"The calibre of attendees from investors, through to large and small biotech and pharma companies was outstanding."
Mark Payton, Fund Principal, Mercia Fund


"An excellent event."
Rebecca Todd, Investment Manager, Oxford Capital Partners


"BioTrinity is an excellent event which highlights some of the quality science developing in the Oxford area."
Jonathan Senior, Director, Nomura Code


"What impressed me about BioTrinity this year is the seniority of the commercial connections whom we met. The event was also attended by a larger number of fellow investors than I expected."
Simon Haworth, Director, IPSO Ventures.


"BioTrinity 2010 was an excellent opportunity to gauge the mood of the sector at this difficult time, and to partner and network with new and existing contacts."
Philip Kendall, Senior Sector Manager, UK Trade & Investment


"The 2009 BioTrinity Conference was an exceptional networking opportunity. Most of the delegates were searching for networking opportunities and OBN provided many different opportunities to make this happen from the relaxed environment of the drinks reception, to the gala dinner and the buffet lunches at the conference. I have just retuned from the 2009 event and next year’s dates have already been marked in my diary."
Jim Rennie, Director, Eviva Pharma Ltd


"A well organised conference with a good mix of industry players which provided lots of good networking opportunities."
Charles Waddell, Partner, Fasken Martineau LLP


"BioTrinity is one of the best partnering meetings and is an important part of our strategy in advancing our company."
Eddy Littler, CEO, Domainex Ltd


"BioTrinity continues to provide me with a great opportunity to network with many of my industry colleagues and to meet new potential customers."
Mark Ashton, EVP Business Development, Evotec UK Limited


"BioTrinity was an excellent event with an interesting mix of biotech, big pharma, service providers and funders. It is certainly the best of its kind being a manageable size for delegates to get the best out of the two days."
David Scales, CEO, GlycoForm Ltd


"BioTrinity was an excellent opportunity to raise our profile and to meet key contacts from pharma and venture capital firms."
James Noble, CEO, Immunocore Ltd


"Excellent venue, lots going on, full of people and companies who I wanted to meet. I fulfilled all my business-related objectives and I enjoyed myself into the bargain!"
John March, CEO, BigDNA Limited


"BioTrinity is the annual event for making sure that one's knowledge of the region's biotech is up to date, and for catching up with contacts in one place - an efficient use of time."
Lisa Mynheer, DiagnOx


"Once again, BioTrinity gave ample opportunity for business development with a highly relevant audience. This has led to several potential pieces of work."
Rod Cook, Partner, Biotech Personnel


"BioTrinity is fast becoming the best UK biotech forum. It is diverse in nature and well attended with a good mix of businesses and service providers. This year's quick fire company presentation was perfect for dipping in and out to balance learning of new technology developments and holding partnering meetings."
Jayne McLaughlin, Director, george james ltd

 


You can also read a further 40 testimonials from recent past years of BioTrinity .





BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
80 global pharma/corporate venture delegates
33 global pharma/medical technology corporates